Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan
{{output}}
Background: Trastuzumab deruxtecan (T-DXd) has demonstrated substantial clinical efficacy in patients with advanced breast cancer; however, predictive and prognostic biomarkers for treatment outcomes remain poorly defined. Host i... ...
